Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-30 and ICE Chemotherapy in Pediatric Recurrent ALCL
NCT00354107Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2007
- Primary completion
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iratumumab in anaplastic large cell lymphoma (ALCL), sponsored by National Cancer Institute. Primary endpoints: Toxicities of SGN-30 alone and in combination with ICE and Antitumor Activity at Week 4. Started Jan 2007; status: terminated.
02
Drugs
iratumumab
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT00354107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354107.